piperidines and libexin

The antitussive Libexin was synthesized in the Research Laboratory of CHINOIN Pharmaceutical and Chemical Works Ltd., Budapest. Observations of the drug in different disease groups have been surveyed on the basis of data published over more than twenty years. According to the unanimous opinion of the authors the drug does not depress respiration, it rather improves the values of the respiratory function. The majority of the examining physicians are on the opinion that it does not hinder expectoration. The drug proved to be of high value in alleviating nocturnal coughing controlling spastic bronchitis in children, as a pretreatment before bronchological examinations and their anaesthesia. It may successfully be used in both acute and chronic bronchitises in preoperative and postoperative cases, in cardiology, otorhinolaryngology and paediatrics.

Topics: Antitussive Agents; Humans; Hungary; Piperidines; Respiratory Tract Diseases; Tablets

Topics: Acute Disease; Adult; Aged; Antitussive Agents; Benzhydryl Compounds; Chronic Disease; Clinical Trials as Topic; Codeine; Cough; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Male; Middle Aged; Oxadiazoles; Piperidines; Propanolamines

The objective of this study was to investigate the human teratogenic potential of oral prenoxdiazine treatment during pregnancy. The analysis of cases with congenital abnormalities and their matched controls without congenital abnormalities was performed in the large population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. Of the 22,843 pregnant women who had offspring with congenital abnormalities, 158 (0.7%) were treated with prenoxdiazine. Of the 38,151 pregnant women who had babies without any defects in the study period (control group), 226 (0.6%) were treated with prenoxdiazine (adjusted prevalence odds ratio, 1.0; 95% confidence interval, 0.8-1.3). The comparison of cases and their matched controls did not show a significantly higher rate of prenoxdiazine treatment during the second and third months of gestation in the total (adjusted prevalence odds ratio, 1.4; 95% confidence interval, 0.9-2.2) or in any group of congenital abnormalities. Treatment with prenoxdiazine during pregnancy did not have any teratogenic risk to the fetus. Thus, prenoxdiazine treatment in pregnant women with an unproductive cough may be beneficial.

Topics: Abnormalities, Drug-Induced; Administration, Oral; Adult; Bacterial Infections; Case-Control Studies; Female; Humans; Hungary; Piperidines; Pregnancy; Pregnancy Complications; Pregnancy Trimester, Second; Pregnancy Trimester, Third

Topics: Antitussive Agents; Cough; Humans; Lung Diseases; Piperidines

Topics: Animals; Antitussive Agents; Cats; Cough; Piperidines

Topics: Humans; Microchemistry; Oxadiazoles; Piperidines; Polarography

Topics: Fluorometry; Oxadiazoles; Piperidines

Topics: Adolescent; Adult; Antitussive Agents; Chronic Disease; Female; Humans; Male; Middle Aged; Oxadiazoles; Piperidines; Respiratory Tract Diseases

The ability of human polymorphonuclear granulocytes and alveolar macrophages from rats to ingest Saccharomyces cerevisiae was tested in vitro in the presence of various concentrations of emetine and libexine. Emetine 4.0 and 40.0 microgram/ml caused an increase in the phagocytic index of polymorphonuclear granulocytes and alveolar macrophages. After oral administration of emetine the phagocytosis-enhancing effect was still apparent. Intracellular killing was not influenced by emetine or libexine.

Topics: Adult; Drug Combinations; Emetine; Female; Humans; In Vitro Techniques; Macrophages; Male; Middle Aged; Neutrophils; Oxadiazoles; Phagocytosis; Piperidines; Pulmonary Alveoli; Saccharomyces cerevisiae